FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
On April 23, 2025, the Food and Drug Administration approved penpulimab-kcqx (Akeso Biopharma Co., Ltd.) with cisplatin or carboplatin and…
Pain and Arthritis Products Containing Hidden Ingredients
Learn about the warnings for pain and arthritis products that contain hidden drugs and other hidden ingredients.
Painflex Forte may be harmful due to hidden drug ingredients
The Food and Drug Administration is advising consumers not to purchase or use Painflex Forte, a product promoted and sold…
Cholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals – 684036 – 07/09/2024
Finished Pharmaceuticals/Unapproved New Drugs
YangZhou SuXiang Medical Instrument Co., Ltd. – 686655 – 07/08/2024
CGMP/Finished Pharmaceuticals/Adulterated
Optikem International Inc. – 680264 – 06/20/2024
CGMP/Finished Pharmaceuticals/Adulterated
Laboratorio Magnachem International – 673796 – 06/18/2024
CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
reBom Co., Ltd. – 682811 – 06/26/2024
CGMP/Finished Pharmaceuticals/Adulterated
Max Chemical Inc. – 682037 – 06/20/2024
CGMP/Finished Pharmaceuticals/Unapproved New Drug/Misbranded/Adulterated
FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products
FDA has become aware of reports of adverse events involving compounded topical finasteride products potentially putting consumers at risk.